In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-fluorouracil

British Journal of Haematology

Volumn 94, Issue 3, 1996, Pages 443-448

  Aidoudi, Sallouha ^a   Guigon, Martine ^b   Lebeurier, Isabelle ^a   Caen, Jacques P ^a   Han, Zhong Chao ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

5 Fluorouracil; AcSDKP; Haemopoiesis; Haemoprotection; Platelet factor 4

Indexed keywords

FLUOROURACIL; SERASPENIDE; THROMBOCYTE FACTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HEMATOPOIESIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029841318     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1821.x     Document Type: Article

References (30)

1. Amiral, J., Bridey, F., Wolf, M., Boyer-Neumann, C., Fressinaud, E., Vissac, A.M., Peynaud-Debayle, E., Dreyfus, M. & Meyer, D. (1995) Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thrombosis and Haemostasis, 73, 21-28.
2. Bindoula, G., Massé, A., Ardouin, P., Sainteny, F. & Carde, P. (1996) Protection de la moelle osseuse par Fassociation AcSDKP-G-CSF chez la souris traitée par radriamycine. (Abstract ). XVth Congress of the French Society of Haematology, Paris. Haematologi and Cell Therapy, 38, 13.
3. Bogden, A.E., Carde, P., Deschamps de Paillette, E., Moreau, J.P., Tubiana, M. & Frindel, E. (1991) Amelioration of chemotherapy induced toxicity by cotreatment with a hematopoiesis-inhibiting letrapeptide AcSDKP. Annals of the New York Academy of Sciences, 628, 126-139.
4. + subpopulations in response to growth factors, Blood, 82, 3307-3314.
5. Bradley, T.R., Hodgson, G.S. & Bertoneello, I. (1982) Characteristics of primitive macrophage progenitor cells with high proliferative potential: relationship to cells with marrow repopulating ability in 5-fluorouracil treated mouse bone marrow. Experimental Hematology Today (ed. by S. J. Baum. G. D. Ledney and D. W. van Bekkum). p. 285. Springer International.
6. Broxmeyer, H.E. (1992) Suppressor cytokines and regulation of myelopoiesis: biology and possible clinical uses. American Journal of Pediatric Hematology/Oncology, 14, 22-30.
7. Carde, P., Mathieu-Tubiana, N., Vuillemin, E., Delwail, V., Corbion, O., Deschanips de Paillette, E., Frindel, E., Guigon, M. & Najman, A. (1993) Phase I II trial of seraspenide (AcSDKP): a suppressor of myelopoiesis protects against chemotherapy myelotoxicity. The Negative Regulation of Hematopoiesis: from Foundamental Aspects to Clinical Application (ed. by M. Guigon, F. M. Lemoine, N. Dainiak, A. Schechter and A. Najman), p. 459, John Libbey Eurotext.
8. Chabner, B.A. & Myers, C.E. (1993) Antitumer antibiotics. Cancer, Principles and Practice of Oncology (ed. by J. R. DeVita, S. Hellman and S. A. Rosenberg), p. 374. Lippincott, Philadelphia.
9. Dunlop, D.J., Wright, E.G., Lorimore, S., Graham, G.J., Holoyoake, T., Kerr, D.J., Wolpe, S.D. & Pragnell, L.B. (1992) Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIPla in vivo. Blood, 79, 2221-2225.
10. Frindel, E. & Monpezat, J.P. (1989) The physiological role of the endogenous colony forming units-spleen (CFU-S) inhibitor acetyl-N-Ser-Asp-Lys-Pro (AcSDKP). Leukemia, 3, 753-754.
11. Grzegorzewski, K., Ruscett, F.W., Usui, N., Damia, G., Longo, D.L., Carlino, J.A., Keller, J.R. & Wiltrout, R.H. (1995) Recombinant transforming growth factor β1 and β2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. Journal of Experimental Medicine, 180, 1047-1057.
12. Guigon, M., Mary, J.Y., Enouf, J. & Frindel, E. (1982) Protection of mice against lethal doses of 1-β-arabinofuranosyl-cytosine by pluripotent stem cell inhibitors. Cancer Research, 42, 638-642.
13. Han, Z.C. (1994) Identification of a murine high-proliferative-potential colony-forming cell (HPP-CFC) capable of producing a number of megakaryocytes and replating for secondary HPP-CFCs in culture. Journal of Laboratory and Clinical Medicine, 123, 610-616.
14. Han, Z.C., Bellucci, S., Bodevin, E., Wan, H.Y., Shen, Z.X. & Caen, J.P. (1991) In vivo inhibition of megakaryocyte and platelet production by platelet factor 4 in mice. Compte Rendu de l'Académie de Sciences, Paris, 313, 553-558.
15. Han, Z.C., Bellucci, S., Tenza, D. & Caen, J.P. (1990a) Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythaemia and immune thrombocytopenic purpura. British Journal of Haematology, 74, 395-401.
16. Han, Z.C., Bellucci, S., Wan, H.Y. & Caen, J.P. (1992a) New insights into the regulation of megakaryocytopoiesis by haematopoietic and fibroblastic growth factors and transforming growth factor β1. British Journal of Heamatology, 81, 1-5.
17. Han, Z.C., Maurer, A.M., Bellucci, S., Wan, H.Y., Kroviarski, Y., Bertrand, O. & Caen, J.P. (1992b) Inhibitory effect of platelet factor 4 (PF4) on the growth of human erythroleukemia cell; proposed mechanism of action of PF4. Journal of Laboratory and Clinical Medicine, 120, 645-660.
18. Han, Z.C., Sensébe, L., Abgrall, J.F. & Brière, J. (1990b) Platelet factor 4 inhibits human megakaryocytopoiesis in vitro. Blood, 75, 1234-1239.
19. Handin, R.I. & Cohen, H.J. (1976) Purification and binding properties of human platelet factor 4. Journal of Biological Chemistry, 251, 6276-6279.
20. Jackson, C.W. (1973) Cholinesterase as a possible marker of early cells of the megakaryocyte. Blood, 42, 413-421.
21. Jackson, J.D., Yan, Y., Ewel, C. & Talmadge, J.E. (1996) Activity of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Experimental Hematology, 24, 475-481.
22. Lebeurier, I., Basara, N., Aidoudi, S., Amiral, J., Caen, J.P. & Han, Z.C. (1996) Carboxy-terminal peptides (C1-24 and C13-24 but not C1-13) of platelet factor 4 inhibit murine megakaryocytopoiesis, an activity which is neutralized by heparin. British Journal of Haematology, 92, 29-34.
23. Lenfant, M., Wdzieczak-Bakala, J., Guittet, E., Prome, J.C., Sotty, D. & Frindel, E. (1989) Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proceedings of the National Academy of Sciences of the United Status of America, 86, 779-782.
24. Long, M.W., Gragowski, L.L., Heffner, C.H. & Boxer, L.A. (1985) Phorbol diesters stimulate the development of an early murine progenitor cell: the burst forming unit-megakaryocyte. Journal of Clinical Investigation, 76, 431-438.
25. McNiece, I.K., Robinson, B.E. & Quesenberry, P.J. (1988) Stimulation of murine colony-forming cells with high proliferative potential by the combination of GM-CSF and CSF-1. Blood, 72, 191-195.
26. Moore, M.A.S. (1991) Clinical implications of positive and negative hematopoietic stem cell regulators. Blood, 78, 1-19.
27. Moore, M.A.S. & Warren, D.J. (1987) Interleukin-1 and G-CSF synergism: in vivo stimulation of stem cell recovery and hematopoietic regeneration following 5-fluorouracil treatment in mice. Proceedings of the National Academy of Science of the United States of America, 84, 7134-7138.
28. Paukovits, W.R., Guigon, M., Binder, K.A., Hergl, A., Laerum, O.D. & Schulte-Hermann, R. (1990) Prevention of hematotoxic side-effects of cytostatic drugs in mice by a synthetic hemoregulatory peptide. Cancer Research, 50, 328-332.
29. Paukovits, W.R., Moser, M.H., Binder, K.A. & Paukovits, J. (1991) Protection from arabinofuranosylcytosine and N-mustard-induced myelotoxicity using hemoregulatory peptide. Blood, 50, 1313-1319.
30. + cord blood cells: comparative studies with transforming growth factor β1. British Journal of Haematology, 93, 265-273.